Simulations Plus’ (SLP) Outperform Rating Reaffirmed at William Blair

William Blair reiterated their outperform rating on shares of Simulations Plus (NASDAQ:SLP) in a research report sent to investors on Thursday, Benzinga reports.

SLP has been the subject of a number of other reports. KeyCorp began coverage on Simulations Plus in a research note on Monday, July 29th. They set an “overweight” rating and a $47.00 price target for the company. BTIG Research lowered their target price on Simulations Plus from $60.00 to $50.00 and set a “buy” rating for the company in a research report on Thursday. JMP Securities initiated coverage on shares of Simulations Plus in a research report on Tuesday, July 16th. They issued a “market perform” rating on the stock. Finally, Craig Hallum reaffirmed a “buy” rating and set a $56.00 price target on shares of Simulations Plus in a research note on Wednesday, July 3rd. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $54.50.

Simulations Plus Stock Performance

SLP traded down $0.48 during trading on Thursday, reaching $30.48. 21,468 shares of the company traded hands, compared to its average volume of 128,810. Simulations Plus has a 12-month low of $29.37 and a 12-month high of $51.22. The firm has a fifty day simple moving average of $33.20 and a 200 day simple moving average of $40.76. The company has a market cap of $609.90 million, a P/E ratio of 64.50 and a beta of 0.69.

Simulations Plus (NASDAQ:SLP) last announced its quarterly earnings results on Wednesday, October 23rd. The technology company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. The company had revenue of $18.70 million for the quarter, compared to the consensus estimate of $19.73 million. Simulations Plus had a net margin of 14.36% and a return on equity of 7.80%. Simulations Plus’s revenue for the quarter was up 19.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.18 EPS. As a group, sell-side analysts expect that Simulations Plus will post 0.54 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Walter S. Woltosz sold 20,000 shares of the firm’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $39.63, for a total value of $792,600.00. Following the completion of the sale, the director now directly owns 3,521,592 shares in the company, valued at $139,560,690.96. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last 90 days, insiders have sold 60,750 shares of company stock valued at $2,145,055. 20.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Simulations Plus

Hedge funds have recently added to or reduced their stakes in the company. nVerses Capital LLC boosted its position in shares of Simulations Plus by 1,100.0% during the third quarter. nVerses Capital LLC now owns 1,200 shares of the technology company’s stock valued at $38,000 after buying an additional 1,100 shares during the period. EntryPoint Capital LLC bought a new stake in shares of Simulations Plus during the 1st quarter worth approximately $57,000. Allspring Global Investments Holdings LLC bought a new stake in shares of Simulations Plus during the 1st quarter worth approximately $70,000. Connecticut Wealth Management LLC purchased a new position in Simulations Plus during the 1st quarter valued at $204,000. Finally, Los Angeles Capital Management LLC bought a new position in Simulations Plus in the 2nd quarter valued at $206,000. 78.08% of the stock is currently owned by institutional investors.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.